Disease Modification of Asthma by molecules derived from TB bacteria

结核菌分子对哮喘疾病的缓解作用

• 批准号: 710703
• 金额: $ 12.74万
• 依托单位: PEPTINNOVATE LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Proof of Concept
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=710703
• 关键词: Disease; Modification; Asthma; molecules; derived

Tuberculosis bacteria (mTB) are present in about 2 billion people worldwide; they haveevolved over millennia to remain hidden in the body by producing proteins that modulate thehost's immune system. These proteins have been shown to interact with and reduce the body'snatural inflammatory processes.Peptinnovate’s innovationPeptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and todevelop new medicines for debilitating diseases such as asthma and COPD. Building onevolution, nature's ingenuity and employing Peptinnovate’s drug discovery and developmentskills we have modified these proteins to more drug-like molecules and are progressing thecandidate molecule, PIN201104, to the clinic.AimsFollowing exciting preclinical data in the murine house dust mite (HDM) asthma model forthe lead candidate PIN201104 Peptinnovate will progress the molecule into in vivo and invitro mechanism of action studies to; unravel the mechanism of action of the peptide inasthma animal models and translate this mechanism into an in vitro setting in human cells.These studies will then lead to an in vitro biomarker assay for use in clinical studies in healthyvolunteers and guide phenotypic positioning of PIN201104 in severe, steroid refractiveasthma.Objectives• To perform in vivo studies in murine asthma models to determine if PIN201104effects airway hyperreactivity (asthma)• To perform in vivo studies to ascertain the appropriate dosing regimen and route ofdelivery for PIN201104 for the treatment of asthmaBenefits, outcomes and impactsThe worldwide market for inflammatory disease treatment is substantial (>$70 billion),however recent safety scares have been attributed to a number of key drugs. Peptinnovate’sparadigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build asustainable UK biotech company

全球约 20 亿人体内存在结核菌 (mTB)；它们经过数千年的进化，通过产生调节宿主免疫系统的蛋白质而隐藏在体内。这些蛋白质已被证明可以与人体的自然炎症过程相互作用并减少其发生。Peptinnovate 的创新Peptinnovate 的方法是释放这些蛋白质的抗炎活性，并开发用于治疗哮喘和慢性阻塞性肺病等衰弱疾病的新药。借助大自然的独创性，并利用 Peptinnovate 的药物发现和开发技能，我们已将这些蛋白质修饰为更多类似药物的分子，并将候选分子 PIN201104 推向临床。 目标 在主要候选药物 PIN201104 的鼠屋尘螨 (HDM) 哮喘模型中获得令人兴奋的临床前数据后，Peptinnovate 将对该分子进行进展 进行体内和体外作用机制研究；揭示肽哮喘动物模型的作用机制，并将该机制转化为人类细胞的体外环境。这些研究随后将产生一种体外生物标志物测定，用于健康志愿者的临床研究，并指导 PIN201104 在严重类固醇折射哮喘中的表型定位。目标• 在小鼠哮喘模型中进行体内研究，以确定是否 PIN201104 影响气道高反应性（哮喘）• 进行体内研究，以确定 PIN201104 治疗哮喘的适当给药方案和给药途径 益处、结果和影响 全球炎症性疾病治疗市场规模巨大（>700 亿美元），然而，最近的安全恐慌归因于许多关键药物。 Peptinnovate 在潜在治疗方案方面的范式转变将对数百万患者的生活产生深远影响，减轻医疗保健提供者的负担，并帮助建立可持续发展的英国生物技术公司